Companion Animal Arthritis Global Market Report 2024

The companion animal arthritis refers to a condition involving inflammation of one or more joints in companion animals such as cats, dogs, and other exotic animals. Companion animal arthritis develops in the bones when the cartilage between joints becomes rougher and more worn, forcing the bone surfaces to rub against one another.

The main type of companion animal arthritis are dogs, cats, and others types. The dogs companion animal arthritis are used for controlling pain and inflammation in dogs. Dogs are domesticated canines (Canis familiaris) that are usually kept as pets or trained for hunting, guarding individuals or property. The companion animal arthritis indication are osteoarthritis and, other arthritis, that are treatment through medication, supplements and other treatment, which are sold and distributed through veterinary hospitals and clinics, retail pharmacies, online stores, and others.

The companion animal arthritis market research report is one of a series of new reports that provides companion animal arthritis market statistics, including companion animal arthritis industry global market size, regional shares, competitors with a companion animal arthritis market share, detailed companion animal arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the companion animal arthritis industry. This companion animal arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion animal arthritis market size has grown strongly in recent years. It will grow from $3.4 billion in 2023 to $3.72 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing pet ownership, advancements in veterinary medicine, awareness and education.

The companion animal arthritis market size is expected to see rapid growth in the next few years. It will grow to $5.47 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to aging pet population, innovations in therapeutics, customized nutrition, telemedicine in veterinary care, humanization of pets. Major trends in the forecast period include biologics in veterinary medicine, digital health solutions, nutraceuticals and functional foods, collaborations and partnerships, pet insurance impact, consumer demand for natural and holistic therapies, data-driven veterinary care.

Rising trend of pet adoption is expected to propel the growth of companion animal arthritis market. Pet adoption helps reduce stress, anxiety, depression, and so on. Pet adoption is a method of getting a dog, cat, and other exotic animals that their prior owners have given up to a shelter or rescue rather than getting one from a pet shop, breeder, or another individual. Pets face the risk of developing arthritis once they start getting into old age. For instance, according to a survey conducted by, The American Pet Products Association, a US-based not-for-profit industry association, approximately half of british homes with pets acquired at least one new animal while the country was in lockdown, while 11.3 million Americans acquired new pets during the pandemic. Additionally, in the survey, 16% of Generation Z respondents and 13% of millennials stated they had adopted a new pet during the pandemic. Therefore, the rising trend of pet adoption contributes significantly to the growth of the companion animal arthritis market.

The increased spending on pet healthcare is anticipated to boost the demand for the companion animal arthritis market over the coming years. Spending on pet healthcare refers to the financial outlay for medical services and treatments aimed at maintaining or improving the well-being of domestic animals. Spending on companion animal arthritis care has risen steadily, reflecting a growing commitment to improving pets' well-being and quality of life. For instance, in 2022, according to the American Pet Products Association Inc., a US-based not-for-profit industry association, the expenditure on supplies, live animals, and OTC medicine is $31.5 billion in 2022 compared to $32.1 billion in 2023 and expenditure on veterinary care and products is $35.9 billion in 2022 compared to 37 billion in 2023. Therefore, increased spending on pet healthcare is driving the growth of the companion animal arthritis market.

Technological innovation is a key trend in the companion animal arthritis market. Technological innovation benefits people by improving productivity and giving them access to freshly produced better goods and services, which raise the general standard. Major players in the industry are using monoclonal antibody therapy to treat companion animal arthritis. Monoclonal antibody therapy is used on companion animals to treat arthritis, immune-mediated disorders, chronic pain, and others. Monoclonal antibodies are antibodies produced by immune cells that are identical clones of a single parent cell. For instance, In April 2021, Zoetis, a US-based pharmaceutical company, launched LIBRELA® and SOLENSIA® in European Union, United Kingdom, and Switzerland to prevent arthritis pain in cats and dogs using monoclonal antibody therapy. It works similarly to naturally produced antibodies, with little involvement of the liver or kidneys in their metabolism and removal of gastrointestinal impact.

Major companies operating in the companion animal arthritis market are focused on developing stem cell treatments to gain a competitive edge in the market. Stem cell treatment is being explored as a promising therapy for animal arthritis, offering potential relief and regeneration of damaged joints. For instance, in January 2023, TVM, a UK-based animal health company, introduced DogStem, the first and only licensed stem cell therapy for canine osteoarthritis in Europe. This innovative treatment is designed for dogs with mild to severe hip and elbow osteoarthritis, and it has demonstrated effectiveness in reducing pain, alleviating lameness, and enhancing mobility and overall quality of life. DogStem boasts long-term efficacy, providing relief for dogs lasting anywhere from 3 to more than 12 months after a single injection. The key active ingredient in this product is mesenchymal stem cells derived from equine umbilical cords, known for their immunomodulatory and anti-inflammatory properties attributed to their paracrine activity.

In September 2022, Zoetis, a US-based animal health company, acquired NewMetrica for an undisclosed amount. This transaction would enhance Zoetis' capacities throughout the continuum of care, expand our grasp of quality-of-life evaluations, and result in a more profound comprehension of an animal's well-being. NewMetrica is a UK-based provider of scientifically-developed instruments to measure quality-of-life in animals such as canine arthritis.

Major companies operating in the in the companion animal arthritis market report are Zoetis Inc., Virbac S. A., Elanco Animal Health Incorporated, C. H. Boehringer Sohn AG & Co. KG, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Vetoquinol S. A., Phibro Animal Health Corporation, NexGen Pharmaceuticals Inc., Norbrook Holdings Limited, Covetrus Inc., Bayer AG, Abbott Laboratories, Qiagen N. V., Becton Dickinson and Company, Quest Diagnostics Incorporated, Hologic Inc., F. Hoffmann-La Roche Ltd., Femasys Inc., Arbor Vita Corporation, VetStem Biopharma Inc., Aratana Therapeutics Inc., Kindred Biosciences Inc., Karyopharm Therapeutics Inc., Regeneus Ltd., VetCell Therapeutics, VetDC Inc., VetPharm Inc., VetStem, VetZ Limited, VetZoo

North America was the largest region in the companion animal arthritis market in 2023. The regions covered in the companion animal arthritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the companion animal arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The companion animal arthritis market includes revenues earned by entities by NSAIDs, monoclonal antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.